Glenmark expands oncology portfolio with new Hengrui partnership

Glenmark Specialty S.A. (GSSA), a subsidiary of Glenmark Pharmaceuticals Ltd., has entered into an exclusive license and collaboration agreement with Hengrui Pharma for Trastuzumab Rezetecan (SHR-A1811), a next-generation HER2-targeting antibody drug conjugate (ADC). This partnership grants Glenmark exclusive rights to develop and commercialize Trastuzumab Rezetecan worldwide, excluding Mainland China, Hong Kong SAR, Macao SAR, Taiwan Region, USA, Canada, Europe, Japan, Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, and Uzbekistan.

Under the terms of the agreement, Glenmark will make an upfront payment of $18m to Hengrui. Additionally, Hengrui is eligible to receive regulatory and commercial milestone payments totaling up to $1.093bn. Glenmark will also pay corresponding royalties to Hengrui based on the net sales of Trastuzumab Rezetecan within the licensed territories.

Trastuzumab Rezetecan was approved in China in May 2025 for adult patients with HER2 (ERBB2) activating mutations in unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received prior systemic therapy. In September 2025, a new indication for Trastuzumab Rezetecan in breast cancer was accepted for review by China's NMPA and included in the priority review program.